In This Article:
Alnylam Pharmaceuticals experienced an 8% price increase over the past week, likely spurred by a positive opinion from the European Medicines Agency (EMA) regarding its RNAi therapeutic, vutrisiran, for treating wild-type or hereditary transthyretin amyloidosis in adult patients. This regulatory milestone possibly provided support against broader market declines, with the Dow Jones, S&P 500, and Nasdaq Composite all witnessing losses after a four-day winning streak. Despite general tech sector setbacks, driven by declines in mega-cap stocks like Nvidia and Tesla, Alnylam's groundbreaking therapeutic developments may have bolstered investor confidence, aiding its recent share performance.
Alnylam Pharmaceuticals has 1 risk we think you should know about.
The recent enthusiasm around Alnylam Pharmaceuticals' positive regulatory feedback for vutrisiran underscores a significant moment for the company, potentially strengthening its growth narrative. The EMA's supportive stance is poised to bolster Alnylam's comprehensive TTR franchise, with revenue projections for TTR products expected to exceed US$1.60 billion by year-end 2025. This momentum may significantly contribute to the company's transition toward profitability, influencing analysts' forecasts for revenue and earnings.
Alnylam's share price, despite recent volatility, has experienced a substantial total return of 84.12% over the past five years. This performance sharply contrasts with the biotech industry, which faced a 5% decline in the last year. The company's projections suggest earnings turning positive within the next three years, with an eventual upswing to US$861.40 million by April 2028. However, Alnylam's current market price of US$236.75 stands at a 25% discount to the consensus price target of US$315.57, indicating potential upside.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.